TABLE 4 

Treatment and outcomes for subjects with staphylococcal PJIc

Treatment or outcome parameterSCVb
Yes (n = 38)No (n = 75)P value
Treatmentd
    Antimicrobial used for initial i.v. therapy0.66
        Vancomycin23 (60.5)45 (60.0)
        β-Lactam/cephalosporin10 (26.3)24 (32.0)
        Daptomycin/linezolid/othera5 (13.2)6 (8.0)
    Duration of i.v. therapy in days, median (range)42 (29–48)42 (1–63)0.23
    Treatment according to Zimmerli/IDSA algorithm38 (100)69 (92.0)0.1
    Initial surgery performed was resection37 (97.4)64 (85.3)0.06
    Antimicrobial-loaded cement spacer used among subjects undergoing resection35 (92.1)62 (82.7)0.25
    No. of subjects reimplanted, n (% of those resected)31 (84)55 (86)
    Duration of time in days between resection and reimplantation, median (range)71 (39–429)64 (35–274)0.21
Follow-up and outcomes
    Duration of follow-up in days, median (range)871 (5–3,795)922 (1–3,778)0.48
    Treatment failure9 (23.7)23 (30.7)0.51
    Duration to failure in days, median (range)142 (65–2,675)219 (2–1,608)0.63
    Reason for treatment failure
        PJI4 (10.5)15 (20.0)
        Further revision for noninfection5 (13.2)7 (9.3)
        Amputation01 (1.3)
    Final joint status
        Functional arthroplasty in place31 (81.6)64 (85.3)0.71
        Resected6 (15.8)7 (9.3)
        Arthrodesis1 (2.6)2 (2.7)
        Amputated02 (2.7)
    No. of surgeries performed, median (range)2 (1–4)2 (1–8)1
  • a One subject received both vancomycin and ceftriaxone due to a single positive culture for Enterobacter cloacae, which, based on retrospective review, was a likely contaminant.

  • b All values indicate number (%) unless otherwise specified.

  • c Continuous variables were compared using Wilcoxon rank sum test; categorical variables were compared using Fisher’s exact test.

  • d Abbreviations: IDSA, Infectious Diseases Society of America; i.v., intravenous.